No major guideline recommends hormone therapy for preventing dementia or Alzheimer's, and randomized trials in midlife have not shown it protects cognition.

Some observational studies suggest lower dementia rates among hormone users, but that pattern may reflect that healthier women are more likely to use hormone therapy in the first place. The most current systematic review, from December 2025, found no significant association between hormone therapy and dementia risk in either direction. Hormone therapy is approved for symptom relief and bone protection, not brain disease prevention, and that is not likely to change without a dedicated prevention trial.

What to know about this answer

Some researchers argue midlife hormone use is associated with lower dementia rates in observational data, and that no trial has tested an early-started, modern regimen for long enough to rule out protection. Guideline bodies counter that every randomized trial with a cognitive endpoint has come back null or harmful, the same pattern that once misled the field on heart disease.

What the research shows, and which source each finding rests on

The Menopause Society's 2022 position statement concludes hormone therapy is not recommended at any age for preventing or treating cognitive decline or dementia.

A[1]

A December 2025 meta-analysis of 10 studies (over 1 million participants) found no significant association between hormone therapy and mild cognitive impairment or dementia risk, in either direction.

A[2]

NICE's 2024 evidence review concluded the evidence does not show hormone therapy meaningfully increases or reduces dementia risk for women starting it around menopause, and recommends against offering it for dementia prevention.

A[3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

the field should keep pursuing brain protection

researchers including Lisa Mosconi and Roberta Diaz Brinton in the literature, and clinically Sharon Malone, Mary Claire Haver, Avrum Bluming, Kelly Casperson

A meta-analysis of 51 observational reports found reduced Alzheimer's risk with hormone therapy use and a 32 percent lower dementia risk with midlife estrogen-only use, backed by an imaging study showing lower amyloid buildup in women randomized to transdermal estradiol.

A[4]

guidelines are right to say no

The Menopause Society, NICE, and the WHI investigators

Every randomized trial with a cognitive or dementia endpoint is null or harmful, including a 10-year follow-up of women who started therapy soon after menopause. The observational protection signal mirrors the pattern that once falsely suggested hormone therapy prevented heart attacks.

B[5]B[6]

What would settle it: A randomized prevention trial in women in their late 40s to 50s using modern formulations, powered for dementia or validated biomarker endpoints and followed for decades. No such trial currently exists.

What is really going on here

  1. Was the dementia warning based on women like me, or on a much older trial population?
  2. Is the number being quoted a relative risk or an absolute risk?
  3. If hormone therapy protected the brain, why did every randomized trial in midlife come back null?

Questions for your doctor

  1. Is hormone therapy being suggested to me for symptom relief, or is dementia prevention part of the reasoning?
  2. How many years am I past my last period, and does that change the risk-benefit picture?
  3. What does current evidence say about my specific situation (age, time since menopause, family history)?
  4. If I am worried about my memory now, is that something hormone therapy is expected to address, or should it be evaluated separately?

Questions with no answer yet

If hormone therapy actually delayed Alzheimer's disease, would a trial short enough to be fundable, and a cognitive test blunt enough for a doctor's office, actually be able to detect that, given the disease unfolds over about two decades?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Existing trials run 4 to 7 years and use screening tools that barely move in healthy midlife women, while dementia has a preclinical phase of about two decades. A null trial result on those terms does not rule out a real, slow-acting effect, and a positive biomarker change does not by itself prove a prevented diagnosis.

What would test it: A trial using imaging or fluid biomarker endpoints instead of only cognitive test scores, run over a much longer follow-up window than any completed to date.

Is the near-total absence of a dedicated hormone-therapy dementia-prevention trial in midlife women a sign the field expects no benefit, or a sign that no one has ever funded and run one?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Guideline bodies explicitly call for a randomized prevention trial with dementia or biomarker endpoints in women in their late 40s to 50s. None exists or is close to completion, and the closest available data, a roughly 10-year follow-up of a 4-year early-therapy trial, found neither benefit nor harm.

What would test it: A publicly or independently funded randomized prevention trial with modern formulations, decades of follow-up, and dementia or validated biomarker endpoints as the primary outcome.

Do the observational studies suggesting protection reflect a real biological effect, or mainly reflect that healthier, more health-engaged women are the ones who use hormone therapy in the first place?

Studied and negative

What is known: Pooled observational studies show about a 22 percent lower Alzheimer's risk among users, but the newest meta-analysis restricted to the strongest study designs found no association in either direction, the same pattern that once wrongly suggested hormone therapy prevented heart attacks.

What would test it: Target-trial-emulation methods designed specifically to separate a true drug effect from healthy-user bias, or the dedicated prevention trial described above.

Sources

  1. 1.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 Hormone Therapy Position Statement of The North American Menopause Society, Menopause 2022 · Systematic review or guideline
  2. 2.Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis.Melville M et al., Lancet Healthy Longev 2025 · Systematic review or guideline
  3. 3.NICE NG23, Menopause: identification and management, 2024 updateSystematic review or guideline
  4. 4.Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia.Nerattini M et al., Front Aging Neurosci 2023 · Systematic review or guideline
  5. 5.Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study.Gleason CE et al. (KEEPS Continuation), PLoS Med 2024 · Randomised trial
  6. 6.Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis.Henderson VW et al. (ELITE), Neurology 2016 · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions